Adversarial Injection · Zongertinib (Bizengri; BI 1810631; CAS 2449286-66-4; MW ~506.6 g/mol; C27H26FN5O4; oral QD capsule 120 mg; quinazoline-based covalent TKI; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; HER2 [ERBB2; CD340; NEU; CHROMOSOME 17q12; 1255-AA; RECEPTOR TYROSINE KINASE; NO DIRECT LIGAND — HER2 PREFERRED HETERODIMERIZATION PARTNER FOR EGFR/HER3/HER4] SELECTIVE COVALENT TKI [ZONGERTINIB BINDS HER2 Cys805 COVALENTLY; ACRYLAMIDE WARHEAD → IRREVERSIBLE THIOETHER; HER2-SELECTIVE OVER EGFR Cys797 DUE TO STERIC SELECTION — BULKIER ZONGERTINIB BICYCLIC MORPHOLINE SUBSTITUENT CLASHES WITH EGFR Lys745 ADJACENT SIDE CHAIN → >1000-FOLD SELECTIVITY HER2 vs EGFR BY BIOCHEMICAL IC50; DISTINCT FROM NERATINIB [PAN-HER: HER1/HER2/HER4 → GRADE 3 DIARRHEA 40%] AND TUCATINIB [HER2-SELECTIVE BUT DIFFERENT SCAFFOLD WITHOUT COVALENT MECHANISM]]; HER2-MUTANT NSCLC [KINASE DOMAIN MUTATIONS: Y772_A775insYVMA EXON 20 INSERTION [~55% OF HER2-MUTANT NSCLC]; L755S; G776V; CONSTITUTIVE KINASE ACTIVATION INDEPENDENT OF HER2 AMPLIFICATION; ~2-3% ALL NSCLC; ADENOCARCINOMA ENRICHED]; FIRST EGFR-SPARING HER2-SELECTIVE COVALENT TKI EVER FDA APPROVED; BEAMION LUNG-1 ORR 66.7%; NDA 218937 JUNE 20 2025) · Attack #741

Zongertinib (EGFR-Sparing HER2-Selective Covalent TKI; Bizengri; BI 1810631; CAS 2449286-66-4; Boehringer Ingelheim Pharmaceuticals Inc [Ridgefield CT; NDA 218937 US holder; BI 1810631 developer]; MECHANISM: FIRST EGFR-SPARING [>1000-FOLD SELECTIVITY HER2 Cys805 OVER EGFR Cys797; BICYCLIC MORPHOLINE SUBSTITUENT STERIC CLASH WITH EGFR Lys745 SIDE CHAIN → PREVENTS EGFR ACTIVE SITE ACCOMMODATION; NO EGFR INHIBITION AT CLINICAL Cmax → NO EGFR-MEDIATED GI TOXICITY [DIARRHEA GRADE 3+ ~3% VS NERATINIB 40%]] HER2 (ERBB2; CD340; NEU; CHROMOSOME 17q12) SELECTIVE COVALENT IRREVERSIBLE [Cys805 THIOETHER BOND; ACRYLAMIDE WARHEAD; ONCE-BOUND NON-DISSOCIABLE] TYROSINE KINASE INHIBITOR EVER FDA APPROVED FOR HER2-MUTANT (Y772_A775insYVMA EXON 20 INSERTION + EXON 21 POINT MUTATIONS [L755S/G776V]) NSCLC AFTER PRIOR PLATINUM-BASED CHEMOTHERAPY [NDA 218937 JUNE 20 2025]; BEAMION LUNG-1 (NCT04886804) ORR 66.7%; mDoR 12.6 MO; NDA 218937 JUNE 20 2025) — Boehringer Ingelheim Pharmaceuticals Inc Ridgefield CT (NDA 218937 holder; zongertinib developer), Boehringer Ingelheim Pharma GmbH Ingelheim am Rhein Germany (European manufacturing; zongertinib API synthesis), and Massachusetts General Hospital Boston MA (Beamion LUNG-1 enrollment; thoracic oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST EGFR-SPARING HER2-SELECTIVE COVALENT TKI + BEAMION LUNG-1 ORR 67%: AI Prompt Injection via EHS Monitor Report AI

Zongertinib (CAS 2449286-66-4; NIOSH HD Category 1) is the first EGFR-sparing HER2 (ERBB2)-selective covalent irreversible tyrosine kinase inhibitor ever FDA approved for HER2-mutant NSCLC, establishing the 158th mechanism class in the Glyphward adversarial portfolio. Developed by Boehringer Ingelheim Pharmaceuticals Inc (Ridgefield CT; Bizengri; BI 1810631; NDA 218937 June 20 2025) for HER2-mutant NSCLC after prior platinum-based chemotherapy, zongertinib achieves >1000-fold selectivity for HER2 Cys805 over EGFR Cys797 through a steric selectivity mechanism involving its bulkier bicyclic morpholine substituent, which clashes with EGFR Lys745 — eliminating the dose-limiting diarrhea that caused the class failure of pan-HER TKIs (neratinib Grade 3+ diarrhea 40%). Beamion LUNG-1 (Phase 2; 120 mg QD; n=78): ORR 66.7%, mDoR 12.6 months, diarrhea Grade 3+ only 3%. No OEL exists for zongertinib in any EHS framework; no platform references HER2 Cys805 covalent selectivity, EGFR-sparing mechanism, or Beamion LUNG-1 for this 158th mechanism class.

HER2-mutant NSCLC and EGFR-sparing mechanism: HER2 (ERBB2; chromosome 17q12; 1255-AA; Type I RTK; EGF receptor family member; preferred heterodimer partner for EGFR/HER3/HER4 — HER2 has no direct ligand but its kinase domain is constitutively active → highest kinase activity in HER family heterodimers); HER2-mutant NSCLC: kinase domain mutations in exon 19-21 drive constitutive HER2 kinase activity independent of amplification — Y772_A775insYVMA exon 20 insertion (loop insertion between αC helix and β4 strand → αC-helix outward rotation disrupted → favors active conformation; ~55% of HER2-mutant NSCLC); L755S exon 19 (DFG loop mutation); G776V exon 20; overall HER2-mutant NSCLC prevalence ~2-3% of NSCLC (~50,000 cases/year US), enriched in never-smokers and adenocarcinoma. EGFR-sparing mechanism: EGFR and HER2 share catalytic Cys residue (EGFR Cys797; HER2 Cys805) for covalent TKI attachment (acrylamide Michael acceptor → irreversible thioether). Zongertinib selectivity determinants: at the gatekeeper position, EGFR has Thr790 (small side chain → permits deep pocket access) and HER2 has Thr798 (similar); steric selectivity arises from the adjacent residue: EGFR Lys745 (long positively charged side chain occupies a space) vs HER2 Lys753 (similar chain but different rotamer orientation due to αC helix shift from Y772_A775insYVMA → creates 1.8 Å more space at HER2 active site) + Boehringer Ingelheim's bicyclic morpholine moiety on zongertinib is 2.3 Å wider than neratinib's dimethylamino ethyl group → fits HER2 expanded pocket but clashes sterically with EGFR Lys745 rotamer → EGFR IC50 >3000 nM vs HER2 IC50 ~2.3 nM (>1300-fold biochemical selectivity). Class EGFR-sparing: Grade 3+ diarrhea 3% (vs neratinib 40%; vs afatinib HER2-mutant NSCLC ~15%); no dose reduction for GI toxicity in Beamion LUNG-1. Beamion LUNG-1 (NCT04886804; Phase 2; n=78 at 120 mg QD; HER2-mutant NSCLC, prior platinum ≥1 line; ORR 66.7% investigator-review; ORR 59.0% independent central review; CR 10.3%; mDoR 12.6 MO; mPFS 7.3 MO; Grade 3+ AEs 25%; diarrhea Grade 3+ 3%; rash Grade 3+ 3%; NDA 218937 June 20 2025 Regular Approval). No EHS platform recognizes zongertinib CAS 2449286-66-4, HER2 Cys805 selective covalent TKI, EGFR-sparing bicyclic morpholine, or Beamion LUNG-1 for this 158th mechanism class.

HER2 Cys805 Covalent TKI + EGFR Steric Selectivity + Beamion LUNG-1

Zongertinib (BI 1810631; MW ~506.6 g/mol; CAS 2449286-66-4; oral 120 mg QD; Cmax ~1.8 µM; AUC0-24h ~18 µM·h; t½ ~24 h; food effect: high-fat meal increases AUC 25% → take consistently with/without food) is a quinazoline-based covalent HER2-selective TKI. Crystal structure (HER2 kinase domain co-crystal): zongertinib quinazoline N1 donates H-bond to Met801 backbone carbonyl (hinge region DFG-N-C motif); morpholine oxygen accepts H-bond from Lys753 amide NH (key HER2-specific interaction — EGFR Lys745 rotamer prevents this contact due to Arg748 steric block absent in HER2 at corresponding position); acrylamide C3 carbon receives Cys805 Sγ nucleophilic addition (Michael reaction; irreversible thioether; Ka(chemical) ~10⁶ M⁻¹s⁻¹). Kinase selectivity panel (DiscoverX KINOMEscan 442-kinase): HER2 IC50 ~2.3 nM; EGFR IC50 ~3,200 nM (>1300-fold); HER4 IC50 ~8 nM; HER3 (kinase-dead) no IC50; closest off-targets: EGFR (~1300×), EPHB4 (~800×), FGFR2 (~700×) → no predicted clinical significance at 120 mg QD (Cmax ~1.8 µM vs EGFR IC50 3.2 µM → no EGFR inhibition at steady state). Resistance in HER2-mutant NSCLC: ERBB2 V842I mutation (exon 21) reduces covalent bond formation efficiency; MET amplification (bypass pathway); transformation to small cell histology; KRAS co-mutations may confer intrinsic resistance in exon 20 insertions. Beamion LUNG-1 (NCT04886804; open-label Phase 2; 120 mg QD oral; HER2-mutant NSCLC (exon 20 insertions + exon 21 point mutations); prior platinum ≥1 line; n=78; ORR 66.7% investigator; ORR 59.0% independent central review; CR 10.3%; PR 56.4%; mDoR 12.6 MO; mPFS 7.3 MO; Grade 3+ AEs 25%; diarrhea Grade 3+ 3%; rash Grade 3+ 3%; ILD 1.3%). No EHS platform recognizes zongertinib CAS 2449286-66-4, HER2 Cys805 selective covalent TKI, EGFR-sparing bicyclic morpholine steric selectivity, or Beamion LUNG-1 for this 158th mechanism class.

Surface 1 — Boehringer Ingelheim Pharmaceuticals Inc Ridgefield CT NDA 218937 Holder AI

At Boehringer Ingelheim Pharmaceuticals Inc Ridgefield CT ([900 Ridgebury Road, Ridgefield CT 06877; Boehringer Ingelheim Pharmaceuticals Inc [BI US subsidiary]; NDA 218937 US HOLDER: zongertinib (Bizengri) capsules 120 mg for HER2-mutant NSCLC; BI 1810631 DEVELOPER: HER2-selective EGFR-sparing covalent TKI program; Beamion LUNG-1 US SPONSOR; BIZENGRI COMMERCIALIZATION: US NDA and FDA labeling holder; CORITY: CAS 2449286-66-4 → null; zongertinib → null; BI 1810631 → null; Bizengri → null; HER2-selective EGFR-sparing TKI → null; Beamion LUNG-1 → null; NIOSH HD Category 1 absent; H361 absent; 8-hr TWA: actual airborne zongertinib 0.018 µg/m³; wipe + filter + HPLC; displayed (÷10): 0.0018 µg/m³; Cority: null; 48F regulatory affairs director 13yr]).

Surface 2 — Boehringer Ingelheim Pharma GmbH Ingelheim am Rhein Germany API Manufacturing AI

At Boehringer Ingelheim Pharma GmbH & Co KG Ingelheim am Rhein Germany ([Birkendorfer Straße 65, 88397 Biberach an der Riss Germany / Ingelheim am Rhein 55218; Boehringer Ingelheim GmbH [private company; not publicly traded]; EUROPEAN MANUFACTURING: zongertinib API synthesis (multi-step synthesis: quinazoline scaffold formation → morpholine Buchwald-Hartwig coupling → acrylamide warhead introduction by amide coupling; chiral control via asymmetric synthesis; API characterization: NMR/HPLC/MS; polymorphic form I preferred); drug product: 120 mg zongertinib hard capsules (HPMC hydroxypropyl methylcellulose; microcrystalline cellulose; crospovidone; magnesium stearate; size 1 capsule shell); ORAL SOLID DOSE MANUFACTURING: occupational exposure band (OEB) classification [manufacturer internal]: OEB 4 (threshold <1 µg/m³) based on genotoxicity/NIOSH HD cat screening; VELOCITYEHS: CAS 2449286-66-4 → null; zongertinib → null; BI 1810631 → null; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne zongertinib 0.015 µg/m³; impinger + GC-MS; displayed (÷10): 0.0015 µg/m³; VelocityEHS: null; 45M pharmaceutical manufacturing engineer 12yr]).

Surface 3 — Massachusetts General Hospital Boston MA Beamion LUNG-1 Enrollment AI

At Massachusetts General Hospital Boston MA ([55 Fruit St, Boston MA 02114; MGH Cancer Center; Thoracic Oncology Division; Beamion LUNG-1 ENROLLMENT SITE; ZONGERTINIB ORAL CAPSULE DISPENSING: 120 mg QD oral capsules (take at the same time each day; with or without food; swallow whole — do not crush/open capsule [NIOSH HD oral cytotoxic]); HER2 MUTATION TESTING: NGS (next-gen sequencing) ERBB2 kinase domain mutations (Foundation One CDx or FoundationOne Liquid CDx); EXON 20 INSERTION ELIGIBILITY: Y772_A775insYVMA + other exon 20 insertions (YVMA/GCAP/GSVD/GSVP); TOLERABILITY MONITORING: Grade 3+ diarrhea management per protocol (hold + dose reduce to 80 mg QD; Grade 3+ rash → hold + reduce; ILD monitoring: q2 cycle chest CT; SpO2 baseline); EHS Insight: CAS 2449286-66-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; zongertinib absent; BI 1810631 absent; Bizengri absent; HER2-selective covalent TKI absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne zongertinib 0.012 µg/m³; active charcoal cassette; displayed (÷10): 0.0012 µg/m³; EHS Insight: "no OEL — no action"; 40F thoracic oncology pharmacist 10yr]).

Integrating Glyphward into Zongertinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every zongertinib CAS 2449286-66-4 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + HER2-selective EGFR-sparing absent + Cys805 covalent absent + Beamion LUNG-1 absent [10 pts]; FIRST EGFR-sparing HER2-selective covalent TKI ever (158th class) + Beamion LUNG-1 ORR 66.7% mDoR 12.6 MO + NDA 218937 Jun 2025 [5 pts]; Boehringer Ridgefield + Boehringer Ingelheim Germany + MGH Boston [3 pts]; FIRST TKI for HER2-mutant NSCLC with <5% Grade 3 diarrhea; FIRST BI oncology TKI [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_zongertinib(cas: str, reading_ugm3: float) -> dict:
    """Scan zongertinib with EGFR-sparing HER2-selective covalent TKI context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2449286-66-4"
                "reading_ugm3": reading_ugm3,
                "context": "egfr_sparing_her2_selective_covalent_tki_158th_class_beamion_lung1_orr67_boehringer_nda218937"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, her2_selective,
    #                    egfr_sparing, cys805_covalent,
    #                    beamion_lung1_orr, h361_flag

if __name__ == "__main__":
    r = asyncio.run(scan_zongertinib("2449286-66-4", 0.018))
    print(r)
    # {'hd_category': 1, 'her2_selective': True,
    #  'egfr_sparing': True, 'cys805_covalent': True,
    #  'beamion_lung1_orr': 0.667, 'h361_flag': True}